Trial to Assess the Safety and Clinical Performance of Contino® in Preventing Urinary Incontinence

NASuspendedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 19, 2019

Primary Completion Date

September 1, 2025

Study Completion Date

December 30, 2025

Conditions
Urinary Incontinence
Interventions
DEVICE

Contino

The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.

Trial Locations (2)

L6H 3P1

The Fe/Male Health Centres, Oakville

M5G 1E2

Dr. Dean Elterman, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CMX Research

OTHER

NCT04165408 - Trial to Assess the Safety and Clinical Performance of Contino® in Preventing Urinary Incontinence | Biotech Hunter | Biotech Hunter